AC Immune (NASDAQ: ACIU): A Catalyst-Loaded Bet Against Amyloid Orthodoxy

The first wave of disease-modifying Alzheimer’s drugs is here. Leqembi from Eisai and Biogen. Kisunla from Eli Lilly. Both opened the market. Both also exposed its limits. They are passive antibodies that require chronic infusion. They carry meaningful ARIA risk. And by most clinical measures, the functional benefit is modest. The next chapter of this market is being written by companies trying something different.

AC Immune (NASDAQ: ACIU) is one of them. The Lausanne-based clinical-stage biopharma trades near $3.00 with a market cap around $300 million. Its pipeline runs across active immunotherapies, tau small molecules, and an NLRP3 inhibitor. Each program targets areas where legacy approaches have fallen short. The April datapoints suggest the next two quarters will determine whether the platform thesis holds.

A Different Bet

Most Alzheimer’s development still routes through amyloid clearance via passive antibodies. AC Immune’s lead program, ACI-24.060, takes a different path. It is an active immunotherapy. The vaccine prompts the patient’s own immune system to generate antibodies against toxic amyloid beta. If it works, duration is longer. Dosing is simpler. The economics shift.

The other shots on goal are deliberately diversified. ACI-7104.056 targets alpha-synuclein in Parkinson’s. The Morphomer Tau small-molecule program is partnered with Lilly. ACI-19764 is a brain-penetrant NLRP3 inhibitor aimed at neuroinflammation.

Big Pharma Is Paying for the Bet

The April 30 update did two things at once. Treatment of the first patient in cohort AD4 of the ABATE trial triggered a $12 million milestone payment from Takeda. Separately, an amendment to the Morphomer Tau collaboration with Lilly secured a CHF 10 million upfront payment in Q2. Under the amended Lilly agreement, AC Immune is eligible for over CHF 1.7 billion in further milestones plus tiered low-double-digit royalties.

Two multinational partners writing fresh checks in the same week is a non-trivial signal for a sub-$300 million market cap. Pharma due diligence is not a substitute for clinical data. But it is the closest thing to external underwriting available to a microcap biotech.

Cash and Calendar

Cash resources of CHF 74.8 million as of March 31, 2026 are expected to fund operations into Q4 2027. That figure excludes the Lilly upfront and the Takeda milestone. Q1 net loss narrowed to CHF 14.8 million from CHF 19.0 million in the prior-year period. The improvement reflects lower spend after last year’s roughly 30% workforce reduction.

The next twelve months are dense with binary readouts:

• 12-month interim results from the AD3 cohort of ABATE in Q2 2026. This is the most consequential near-term datapoint.
• Full data from Part 1 of the ACI-7104 VacSYn Phase 2 trial in Parkinson’s in H2 2026.
• Phase 1 SAD/MAD data for NLRP3 inhibitor ACI-19764 later in 2026.
• Continued IND-enabling progress on the Morphomer tau program.

What the Market Is Pricing

Coverage is sparse but constructive. Leerink reiterated Outperform with a $9 price target after the April update. BTIG maintains a Buy at $8. Across four covering analysts, the average target sits around $10, with a range of $7 to $16. Against a stock near $3, that is the kind of asymmetry catalyst-driven microcap biotech typically prices.

The Skeptical Read

Active immunotherapy in Alzheimer’s has a difficult history. Earlier vaccine programs ran into immunogenicity and safety issues. The approach was sidelined for years. ACI-24.060 has shown an encouraging early profile. The Q2 interim is the first real test of whether this generation clears the bar previous attempts could not.

Alpha-synuclein has similarly humbled well-funded programs across the industry. The tau collaboration with Lilly remains preclinical. The CHF 1.7 billion in potential milestones is contingent on a long sequence of events, not a near-term cash flow.

The capital position helps. It does not eliminate dilution risk. A clean Q2 readout would reset the financing setup materially. A disappointing one would compress it.

The Setup

What makes ACIU interesting at this price is not any single program. It is the combination. Partner-validated platforms. A stated cash runway into Q4 2027 that covers the next several readouts. A calendar that puts genuine clinical proof points within the next two quarters.

The next data point sits on the calendar.

This is not investment advice. Clinical-stage biotech is volatile and binary trial outcomes can produce significant losses. ACIU is a microcap with concentrated catalyst risk. Do your own diligence.